Kim Rosko

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

Rajesh Krishna, Matt S. Anderson, Arthur Bergman et al. · The Lancet · 2007 · 276 citations

Metabolic Syndrome, Hypertension, Healthy Individuals +10

The Acyclic CB1R Inverse Agonist Taranabant Mediates Weight Loss by Increasing Energy Expenditure and Decreasing Caloric Intake

Carol Addy, Hamish Wright, Koen Van Laere et al. · Cell Metabolism · 2008 · 200 citations · Full text

Obesity, Metabolic Syndrome, Caloric Restriction +11

Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice

Lauren P. Shearman, Kim Rosko, R. Fleischer et al. · Behavioural Pharmacology · 2003 · 186 citations

Anorectic Effects, Food Intake, Psychopharmacology +18

Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents

Tung M. Fong, Xiao-Ming Guan, Donald J. Marsh et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 100 citations

Multiple‐Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, in Healthy Male Volunteers

Carol Addy, Paul Rothenberg, Susie Li et al. · The Journal of Clinical Pharmacology · 2008 · 49 citations · Full text

Accumulation Half-life, Pharmacotherapy, Multiple-dose Pharmacokinetics +17